SPOTLIGHT: Biocon denies buyout report
Biocon caused a stir this morning after an Indian financial newspaper claimed the country's biggest biotech was nearing a $400 million buyout deal with a U.S. company. But Biocon executives moved quickly to squelch the story, saying the report was "speculative" and inaccurate. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
